These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1563378)

  • 61. POPULATION PHARMACOKINETICS OF CEFTAZIDIME AFTER A SINGLE SUBCUTANEOUS INJECTION AND NORMAL ORAL AND CLOACAL BACTERIAL FLORA SURVEY IN EASTERN HELLBENDERS (
    Musgrave KE; Hanley CS; Papich MG
    J Zoo Wildl Med; 2021 Apr; 52(1):90-96. PubMed ID: 33827165
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disposition of ceftazidime in surgical patients with intra-abdominal infection.
    Heim-Duthoy KL; Bubrick MP; Cocchetto DM; Matzke GR
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1845-7. PubMed ID: 3072925
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ceftazidime pharmacokinetics in preterm newborns on the first day of life.
    Padovani EM; Fanos V; Dal Moro A; Chiaffoni GP; Fostini R; Girelli M; Boner A
    Biol Res Pregnancy Perinatol; 1986; 7(2):71-3. PubMed ID: 3524697
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.
    König C; Braune S; Roberts JA; Nierhaus A; Steinmetz OM; Baehr M; Frey OR; Langebrake C; Kluge S
    J Antimicrob Chemother; 2017 May; 72(5):1433-1440. PubMed ID: 28175308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.
    Walstad RA; Dahl K; Hellum KB; Thurmann-Nielsen E
    Eur J Clin Pharmacol; 1988; 35(3):273-9. PubMed ID: 3053209
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn.
    Van Den Anker JN; Van Der Heijden BJ; Hop WC; Schoemaker RC; Broerse HM; Neijens HJ; De Groot R
    Pediatr Res; 1995 Nov; 38(5):808-11. PubMed ID: 8552453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis.
    Lubasch A; Lück S; Lode H; Mauch H; Lorenz J; Bölcskei P; Welte T;
    J Antimicrob Chemother; 2003 Mar; 51(3):659-64. PubMed ID: 12615868
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics of ceftazidime after regional limb perfusion in standing horses.
    Oreff GL; Tatz AJ; Dahan R; Segev G; Haberman S; Britzi M; Kelmer G
    Vet Surg; 2017 Nov; 46(8):1120-1125. PubMed ID: 28952152
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
    Boselli E; Breilh D; Rimmelé T; Poupelin JC; Saux MC; Chassard D; Allaouchiche B
    Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Pharmacokinetics of ceftazidime in healthy and renal failure subjects].
    Leroy A; Fillastre JP; Humbert G; Borsa F; Leguy F; Spencer GR
    Presse Med; 1988 Oct; 17(37):1917-20. PubMed ID: 2973585
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime.
    Giri P; Patel H; Srinivas NR
    Drug Res (Stuttg); 2019 May; 69(5):245-255. PubMed ID: 30296806
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Penetration of ceftazidime into intracranial abscess.
    Green HT; O'Donoghue MA; Shaw MD; Dowling C
    J Antimicrob Chemother; 1989 Sep; 24(3):431-6. PubMed ID: 2681122
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
    Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
    Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics of ceftazidime in elderly patients.
    Higbee MD; Swenson E; Gooch WM
    Clin Pharm; 1989 Jan; 8(1):59-62. PubMed ID: 2643501
    [No Abstract]   [Full Text] [Related]  

  • 76. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Penetration of ceftazidime into extracellular fluid in patients.
    Hoffstedt B; Walder M
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():289-92. PubMed ID: 19803000
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats.
    Abd El-Aty AM; Goudah A; Zhou HH
    Pharmacol Res; 2004 May; 49(5):487-91. PubMed ID: 14998560
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of ceftazidime in patients undergoing peritoneal dialysis.
    Tourkantonis A; Nicolaidis P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():263-7. PubMed ID: 6352629
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmacokinetics of recombinant interleukin 2 in humans.
    Konrad MW; Hemstreet G; Hersh EM; Mansell PW; Mertelsmann R; Kolitz JE; Bradley EC
    Cancer Res; 1990 Apr; 50(7):2009-17. PubMed ID: 2317789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.